Analysis of Costs for Imaging-Assisted Pharmaceutical Intervention in Alzheimer’s Disease with Lecanemab: Snapshot of the First 3 Years

FDA approves Alzheimer’s drug lecanemab amid safety concerns

(2023) Sara Reardon   NATURE

Alzheimer’s disease: FDA approves lecanemab amid cost and safety concerns

(2023) Elisabeth Mahase   BMJ-British Medical Journal

Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US

(2022) Eric L. Ross et al.   JAMA Neurology

What to Know About the Alzheimer Drug Aducanumab (Aduhelm)

(2022) Steven Woloshin et al.   JAMA Internal Medicine

Lecanemab in Early Alzheimer’s Disease

(2022) Christopher H. van Dyck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Review of Quantitative Methods for the Detection of Alzheimer’s Disease with Positron Emission Tomography

(2022) Jarrad Perron et al.   Applied Sciences-Basel

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease

(2021) Rik Ossenkoppele et al.   JAMA Neurology

Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA

(2021) Sam Gandy et al.   Molecular Neurodegeneration

Deep learning for Alzheimer's disease: Mapping large-scale histological tau protein for neuroimaging biomarker validation

(2021) Daniela Ushizima et al.   NEUROIMAGE

The characterisation of subjective cognitive decline

(2020) Frank Jessen et al.   LANCET NEUROLOGY

Reversible predictors of reversion from mild cognitive impairment to normal cognition: a 4-year longitudinal study

(2019) Hiroyuki Shimada et al.   Alzheimers Research & Therapy

Discovery of N-(4-[18F]Fluoro-5-methylpyridin-2-yl)isoquinolin-6-amine (JNJ-64326067), a New Promising Tau Positron Emission Tomography Imaging Tracer

(2019) Frederik J. R. Rombouts et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cross-sectional associations between [18F]GTP1 tau PET and cognition in Alzheimer's disease

(2019) Edmond Teng et al.   NEUROBIOLOGY OF AGING

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences

(2019) Arno de Wilde et al.   Alzheimers Research & Therapy

Diagnosis and Management of Dementia: Review

(2019) Zoe Arvanitakis et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Prevalence of Dementia: A Systematic Review and Meta-Analysis

(2019) Qing Cao et al.   JOURNAL OF ALZHEIMERS DISEASE

Preclinical Evaluation of 18 F-JNJ64349311, a Novel PET Tracer for Tau Imaging

(2017) Lieven Declercq et al.   JOURNAL OF NUCLEAR MEDICINE

Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease

(2017) Spencer A. W. Lee et al.   Alzheimers Research & Therapy

Suspected non-Alzheimer disease pathophysiology — concept and controversy

(2016) Clifford R. Jack et al.   Nature Reviews Neurology

A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers

(2016) Clifford R. Jack et al.   NEUROLOGY

Estimation of radiation dose to patients from[18]FDG whole body PET/CT investigations using dynamic PET scan protocol

(2015) BilikereS Dwarakanath et al.   INDIAN JOURNAL OF MEDICAL RESEARCH

Tau pathology and neurodegeneration

(2013) Maria Grazia Spillantini et al.   LANCET NEUROLOGY

Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010

(2012) Thomas G. Beach et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

How golden is the gold standard of neuropathology in dementia?

(2011) Philip Scheltens et al.   Alzheimers & Dementia

Amyloid imaging in prodromal Alzheimer's disease

(2011) Rik Ossenkoppele et al.   Alzheimers Research & Therapy

Clinicopathological Concordance in Dementia Diagnostics

(2009) Hans Brunnström et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY